Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0243026 (
sepsis
)
52,417
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Sepsis
or septic shock is frequently associated with activation of the complement system, coagulation and fibrinolytic changes and the release of several cytokines. In this study we analyzed the relation of complement activation to the inflammatory mediators, hemodynamic and biochemical parameters and severity of illness and outcome in 20 consecutive patients with clinically defined
sepsis
. Levels of C3a and C3d were elevated in 90% of the patients (median levels 0.19 mg/l and 8.6 mg/l respectively) in comparison to 14% and 42%, respectively of 7 patients with non-septic shock. Levels of C4 were decreased in only 1 of the 20 septic patients. Levels of TNF and IL-6 were elevated in 94% and 100% of the patients, Levels of TNF and IL-6 were elevated in 94% and 100% of the patients, respectively (median levels 122 ng/l and 1300 U/ml) and were clearly interrelated (r = 0.67, p less than 0.01). C3a levels correlated with the APACHE II score (r = 0.57, p less than 0.05) and high C3a levels were associated with fatal outcome (p less than 0.05). C3a was also correlated inversely with mean arterial pressure (r = 0.50, p less than 0.01). Levels of complement C3a and C3d significantly correlated with levels of
plasminogen activator inhibitor-1
(
PAI
) and correlated inversely with AT-III levels. We found no correlation between these complement products and leukocyte counts or lactate levels, nor was there a correlation between C3a or C3d and the cytokines TNF and IL-6. Levels of C3a and C3d did not decrease significantly during the first 24 h of treatment, in contrast to a clear decrease in IL-6 levels in all patients and a decrease in TNF in the surviving patients. TNF levels remained stable or increased in the non-survivors. We conclude that both the complement system and the cytokine system are involved in the pathogenesis of septic shock and may be involved in the development of some of the fatal complications like hypotension and disseminated intravascular coagulation.
...
PMID:Complement activation and the production of inflammatory mediators during the treatment of severe sepsis in humans. 164 97
Sepsis
is often associated with hemostatic dysfunction. This study aimed to relate changes in fibrinolysis and coagulation parameters to
sepsis
and
sepsis
outcome. Urokinase-type plasminogen activator (u-PA) antigen, tissue-type plasminogen activator (t-PA) antigen and activity, plasminogen activator inhibitor (PAI) type 1 antigen, PAI activity, antithrombin (AT) III activity, and protein C activity were measured in 24 patients suffering from
sepsis
or septic shock and the results were compared with those observed in 30 non-
sepsis
patients with severe infectious disease. The u-PA level was markedly increased in plasma of
sepsis
patients as compared to non-
sepsis
patients (11.5 +/- 9.4 versus 1.6 +/- 1.5 ng/ml, p less than 0.0001).
PAI-1
antigen and t-PA activity showed a significant increase in
sepsis
patients (320 +/- 390 ng/ml versus 120 +/- 200 ng/ml, and 3.0 +/- 3.6 IU/ml versus 1.0 +/- 0.7 IU/ml, respectively, p less than 0.01). AT III was decreased in
sepsis
patients (58 +/- 28% in
sepsis
versus 79 +/- 26% in severe infectious disease, p less than 0.01) as was protein C (30 +/- 18% versus 58 +/- 27%, p less than 0.001). No significant difference was found for t-PA antigen nor for PAI activity. Nonsurvivors of
sepsis
were distinguished mainly by a high u-PA antigen level and increased t-PA activity. It is concluded that plasma u-PA antigen showed the strongest significant difference, among the parameters evaluated, between
sepsis
and severe infection. u-PA antigen may be of prognostic value in patients admitted to the medical intensive care unit for severe infectious disease.
...
PMID:Fibrinolysis and coagulation in patients with infectious disease and sepsis. 190 55
The regulation of type 1 plasminogen activator inhibitor (
PAI-1
) gene expression was studied in vivo employing a murine model system. Nuclease protection analysis revealed relatively high concentrations of
PAI-1
mRNA in the aorta, adipose tissue, heart, and lungs of untreated CB6 (BalbC X C57B16) mice. Treatment of CB6 mice with LPS, TNF-alpha, or transforming growth factor-beta (TGF-beta) increased the steady-state levels of
PAI-1
mRNA within 3 h in all tissues examined. However, the greatest responses to TGF-beta were observed in adipose tissue and the kidney, while LPS and TNF-alpha strongly stimulated
PAI-1
gene expression in the liver, kidney, lung, and adrenals. In C3H/HeJ mice, which exhibit defective TNF-alpha release in response to LPS, the response of the
PAI-1
gene to LPS was severely attenuated. However, injection of these mice with TNF-alpha increased
PAI-1
mRNA in a tissue-specific pattern strikingly similar to that observed in LPS-treated CB6 mice. These results demonstrate that the
PAI-1
gene is regulated in a complex and tissue-specific manner in vivo, and suggest a role for TNF-alpha in the response of the
PAI-1
gene to
sepsis
.
...
PMID:Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. 191 85
We have determined the plasma concentrations of types 1 and 2 of plasminogen activator inhibitor (
PAI-1
and PAI-2), tumor necrosis factor (TNF-alpha) and endotoxin in 47 patients with bacterial infection (22 patients presented with positive blood cultures). Results were compared with those observed in 30 healthy subjects. There was a significant increase in
PAI-1
and TNF-alpha in patients as compared to controls (p less than 0.0001), whereas no differences for PAI-2 were observed.
PAI-1
and TNF-alpha were significantly higher in 18 patients with gram-negative bacteremia as compared to all other patients (p less than 0.0001). However, no correlation between the analyzed parameters and either endotoxin or clinical outcome was observed. We conclude that there is an increase of
PAI-1
and TNF-alpha in patients with
sepsis
, which is not related to the endotoxin concentration. Our results suggest that
PAI-1
, but not PAI-2, is the main plasminogen activator inhibitor in human
sepsis
.
...
PMID:Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis. 227 26
Impaired fibrinolysis may contribute to development of adult respiratory distress syndrome (ARDS). Pathologic increases in endogenous plasminogen activator inhibitor (
PAI-1
) may blunt normal fibrinolysis and unmask alternate fibrinolytic mechanisms, such as elastase-induced fibrin degradation. We measured
PAI-1
and elastase-induced fibrin(ogen) degradation products in 69 critically ill patients in our medical intensive care unit (MICU) and in nine healthy volunteers. Factor VIII-related antigen protein (VIII:Ag), a reported marker of acute lung injury, and alpha-1-protease inhibitor (alpha-1-PI), an acute phase reactant, were also measured. MICU patients included 24 control patients with no known risk of ARDS, 35 patients with risk factors for ARDS including
sepsis
, pneumonia, aspiration, and shock, and 12 patients with ARDS including two patients from at-risk groups who developed ARDS. Plasma
PAI-1
was determined by chromogenic assay, elastase-induced peptides by a new radioimmunoassay, VIII:Ag by immunoelectrophoresis, and alpha-1-PI by immunodiffusion. When compared to normal volunteers, MICU control patients had elevated
PAI-1
, VIII:Ag, elastase-induced peptides, and alpha-1-PI. Patients with ARDS had significantly higher
PAI-1
and VIII:Ag than did MICU control patients; elastase-induced peptides and alpha-1-PI were not higher. However, at-risk patients who did not develop ARDS also had high
PAI-1
or VIII:Ag. Although these data cannot refute the possible role of these compounds in the pathogenesis of ARDS, they demonstrate that
PAI-1
and VIII:Ag may be elevated in many critically ill patients but may not be useful markers for the subsequent development of ARDS.
...
PMID:Fibrinolysis in critically ill patients. 250 87
Induction of leukocytopenia by cytotoxic drugs protects against the generalized Shwartzman reaction induced by endotoxin. To elucidate the relationship between leukocyte number and in haemostatic and fibrinolytic disturbances in human
sepsis
, we studied 32 septic patients with abnormal leukocyte counts. Twenty patients had
sepsis
in the setting of leukopenia after chemotherapy for haematological malignancies. Twelve patients with leukocytosis developed
sepsis
associated with benign disorders. Concentrations of thrombin-antithrombin III complex (TAT),
plasminogen activator inhibitor-1
(
PAI-1
) and plasma thrombomodulin (TM) in the leukocytosis group of (12.0 +/- 11.0, 40.2 +/- 27.0 and 5.5 +/- 2.3 ng/ml, respectively) were significantly elevated compared to the leukopenia group of (3.8 +/- 2.3, 18.0 +/- 15.0 and 3.1 +/- 1.0 ng/ml, respectively) and controls (3.3 +/- 0.4, 10.5 +/- 5.3, 3.0 +/- 0.5 ng/ml, respectively). On the other hand, there were no significant differences in these values between leukopenia group and controls. Thus leucocytes may play important roles in thrombin generation,
PAI-1
release and injury to endothelial cells.
...
PMID:Haemostatic and fibrinolytic parameters in septic patients with leukopenia or leukocytosis. 772 Aug 38
Thirteen patients (median age, 20 years) with life-threatening primary septic shock (10 meningococcal, 3 pneumococcal infections) were studied prospectively. All had a short history of
sepsis
(< or = 24 h) and no severe underlying disease. Two (15%) died. The logarithm of the initial plasma levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, IL-6, IL-1 receptor antagonist (ra), and plasminogen activator inhibitor (PAI)-1 correlated significantly with APACHE II scores (r2 = .67, .57, .68, .81, and .68, respectively). The plasma levels of endotoxin, TNF-alpha, IL-1 beta, and
PAI-1
decreased toward normal levels within the first 24 h of treatment, but IL-6 and IL-1ra levels remained high until clinical recovery. On admission, the molar excess of IL-1ra to IL-1 beta was > 2000-fold in 11 of the 13 patients. Acute plasmapheresis in 11 of the 13 patients significantly increased the plasma clearance of TNF-alpha (P = .02).
...
PMID:Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. 779 35
This study explored the relationship between cytokines (TNF, IL-1, IL-6), coagulation and fibrinolytic factors in the early stage of
sepsis
syndrome and the relation between these factors with the severity of inflammatory illness as measured by the Simplified Acute Physiology Score (SAPS). Twenty-one normal controls were compared to 34 patients divided into three categories ranging from uncomplicated postoperative patients, to patients with severe infectious conditions including septic shock. A major hemostatic imbalance was demonstrated with particularly marked reduction in fibrinolytic activity [drop of antithrombin III (ATIII) and protein C with an increase of plasminogen activator inhibitor (
PAI-1
) levels] which were directly correlated with the severity of the inflammatory state. Both ATIII and
PAI-1
levels were correlated with the levels of TNF and IL-6 and the severity of illness as measured by SAPS. We established an index, ATIII/
PAI-1
antigen that is significantly different among the four groups (p < 0.001) and strongly correlated with the SAPS (p < 0.001). As
PAI-1
could be secreted not only by TNF activating endothelial cells but also by hepatocytes activated by insulinemia, treatment of
sepsis
with cytokine-specific agents might be of limited effect.
...
PMID:Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state. 795 54
We measured various coagulable factors and molecular markers in plasma and serum in the disease group including DIC, DIC suspect, thrombosis, acute myocardial infarction, angina pectoris,
sepsis
, malignant tumor and type II diabetes and the healthy subject group, and surmised the intravascular coagulative-fibrinolytic activity in each disease group compared with the healthy group. Additionally we selected parameters useful for early detection of the pre-thrombotic state and hypercoagulable state. As a result, of the parameters for the coagulative system, those considered useful were the assay of soluble fibrin monomer complexes using the synthetic substrate (FM.Oita), assay of soluble fibrin monomer complexes using HPLC(SFMC.Oita) and thrombin-anti-thrombin III complex (TAT) in this order. Of the parameters for the fibrinolytic system, those considered useful were FDP assay using ELISA (FDP.Oita) and plasmin-alpha 2 plasmin inhibitor complex (PIC). This FDP.Oita had a considerably high detection sensitivity compared with the FDP assay (Diayatron Co.) using the latex photometric immunoassay which has been commercially available. When measurement was made with plasma and serum in the subject disease group as the sample by the high sensitivity assays mentioned above, it was made clear that both the coagulative activity and fibrinolytic activity are increased, albeit with some differences in intensity, in all the disease groups compared with the healthy group. In order for the hypercoagulable state and pre-thrombotic state to be detected, it is important to know the balance between the coagulative activity and fibrinolytic activity. According to the results of the present experiment, a significant directly proportional correlation was recognized between FM.Oita and FDP.Oita and between TAT and FDP.Oita. Therefore, examination of these ratios will be a more detailed indicator of coagulative-fibrinolytic activity than the TAT/PIC ratio,
PAI-1
/TPA ratio and ATIII/alpha 2 PI ratio hitherto in use. If useful molecular markers such as FM.Oita are measured over time in various cases and these data are compiled and analyzed statistically, it will not be long before the criteria for the hypercoagulable state and pre-thrombotic state are established.
...
PMID:[Molecular marker for detecting hypercoagulable state]. 810 79
Vascular endothelial-PMN interactions are critical reactions in the development of organ failure. Both cell types are activated by LPS and proinflammatory cytokines in
sepsis
. Reactions that are collectively referred to as endothelial activation include expression of procoagulant activity and increased adhesiveness of the endothelium for leukocytes. Some parameters, which are related to endothelial activation are significantly changed during
sepsis
and altered by anti-TNF therapy (e.g.
PAI-1
, thrombomodulin), while others (e.g. sELAM) are increased by
sepsis
but not influenced by anti-TNF therapy. Leukocyte activation (accompanied by elastase release) leads to rearrangement of the CD11/CD18 structures and thereby increased adherence.
...
PMID:Endothelial and leukocyte activation in experimental polytrauma and sepsis. 825 Aug 12
1
2
3
4
5
6
7
8
9
10
Next >>